Financial Data and Key Metrics Changes - The company reported third quarter revenue of $408 million, representing a 143% increase year-over-year, or a 6% increase on a pro forma basis [33] - Adjusted EBITDA for Q3 was $44 million, up from $22 million in the same quarter last year, with an adjusted EBITDA margin of 11% [38] - Funded backlog at the end of the quarter was $1.1 billion, with an unfunded backlog of approximately $3 billion [32] Business Line Data and Key Metrics Changes - The Autonomous Systems segment accounted for 68% of overall revenue, with significant growth driven by products like Puma, JUMP 20, and the Switchblade family [14][15] - The Space, Cyber, and Directed Energy segment recognized $121.9 million in revenue, reflecting a 19% decline year-over-year due to the SCAR program's stop work order [34] - The Uncrewed Aircraft Systems within the Autonomous Systems segment saw over a 50% increase in revenue compared to the pro forma FY 2025 third quarter results [34] Market Data and Key Metrics Changes - The company has seen strong demand for its AI-enabled autonomous drones and counter-UAS solutions, positioning it well in a high-growth market [8][9] - The company is actively engaged with international allies, including Taiwan, Japan, and South Korea, for its autonomous systems [18] - The demand for cost-efficient solutions in the defense sector is unprecedented, with a focus on transitioning programs to commercial product solutions [8][10] Company Strategy and Development Direction - The company is focused on leveraging operational capabilities and driving long-term value creation, with a strategy to transition certain programs to commercial products [6][10] - The expansion of manufacturing capacity, including a new facility in Salt Lake City, is aimed at meeting increased demand and improving profitability [9][10] - The company is committed to developing innovative solutions that align with customer needs, particularly in the Space and Directed Energy segments [11][12] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that the third quarter results fell below expectations due to revenue timing and adjustments in the Space business, but expressed confidence in achieving record fourth quarter revenue [5][27] - The urgency for defense capabilities has increased due to global conflicts, which is expected to drive demand for the company's products [28][71] - Management remains optimistic about the growth trajectory, citing strong order flow and a funded backlog that supports future revenue growth [7][43] Other Important Information - The company is undergoing a transition following the retirement of its CFO, who has been instrumental in increasing the market cap from approximately $1 billion to over $10 billion [29][41] - A goodwill impairment of $151 million was recorded due to the SCAR program's stop work order, impacting the financial outlook for the year [31][32] Q&A Session Summary Question: Long-term prospects of SCDE without SCAR - Management indicated that while the SCAR program's termination is a setback, they remain confident in other high-demand products within the Space and Directed Energy business [52][53] Question: Revenue expectations from SCAR for fiscal 2026 - Management stated that the impact of SCAR on fiscal 2026 revenue is included in their guidance, and it is expected to be less than 5% of total revenue [64][65] Question: Progress on Army programs and timing for awards - Management confirmed active engagement with the U.S. Army on multiple fronts, including recent contract awards for Switchblade products, and expressed optimism about future orders [67][69] Question: Demand acceleration due to the Iran war - Management noted an unprecedented increase in demand for various products, including the Freedom Eagle-1 and Red Dragon, due to ongoing conflicts [70][71] Question: Updates on directed energy portfolio and key programs - Management highlighted strong demand for directed energy systems and the potential for increased orders, emphasizing their unique position in the market [76][79]

Financial Data and Key Metrics Changes - The company reported a consolidated adjusted EBITDA of $69.7 million for fiscal 2025, representing a 48% year-over-year increase, exceeding the previous guidance of $60-$65 million [11][12] - Consolidated net sales increased by 40% over 2024, while the reported net loss was $90.4 million due to continued investments in the Conway facility [12][14] - The Beverage Solutions segment adjusted EBITDA was $68.5 million, up 28% from 2024, while the SS&T segment adjusted EBITDA more than doubled to $16.5 million from $6.4 million in 2024 [11][14] Business Line Data and Key Metrics Changes - The Beverage Solutions segment's growth was driven by the launch of the RTD can line and a 29% increase in single-serve cup volumes [13][14] - The SS&T segment capitalized on coffee price volatility, achieving significant EBITDA growth [14] Market Data and Key Metrics Changes - The company ended 2025 with a Beverage Solutions secured net leverage ratio of 3.85 times, better than the targeted 4.5 times [11][12] - The company expects to be free cash flow positive in the second half of 2026, marking a significant milestone after three years of heavy investment [17] Company Strategy and Development Direction - The company aims to become the premier integrated strategic supplier for coffee, tea, energy, and high-protein beverage brands globally [5][10] - The focus for 2026 is on driving growth through expanded customer volumes and optimizing the customer mix to maximize margins [12][17] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging macroeconomic and geopolitical environment for 2026 but expressed confidence in the company's operational performance due to the completion of the Conway facility [17] - The company anticipates EBITDA growth of 29%-44% in 2026, despite the loss of a significant single-serve customer [17][20] Other Important Information - The company has completed the product development for its first high-protein beverage, with production expected to begin in the fall [6] - Capital expenditures are projected to decrease significantly from $89 million in 2025 to approximately $30 million in 2026, indicating a shift in capital intensity [16] Q&A Session Summary Question: Can you size up the EBITDA contribution of the customer that came off the platform on the single-serve side in 2025? - The annualized run rate was about $30 million expected in 2026, with a half-year performance in 2025 [20][21] Question: How far into the process are you of leveraging Palantir's expertise? - The company iterates daily with Palantir, focusing on trade and logistics, and is now turning sights on optimizing all software services [25][26] Question: What is the pacing for winning back customers in the single-serve cup space? - Some customers might show up in late 2026, with all expected to be running by late 2027 [32][33] Question: Can you expand on optimizing product mix to drive margin? - The company is excited about new high-protein offerings and optimizing operations to handle various beverage types [34][36] Question: How is capacity utilization progressing at the Conway plant? - Capacity utilization is expected to increase in 2026, with significant ramp-up anticipated by 2027 [44][45] Question: How does the mix between gross margin and cost leverage help EBITDA for 2026? - SG&A costs are expected to remain flat or decrease, while leveraging the platform will enhance EBITDA growth [46][51]

Financial Data and Key Metrics Changes - Blend Labs, Inc. reported total revenue of $32.4 million for Q4 2025, representing a 7% year-over-year increase and coming in near the high end of revenue guidance [39] - Non-GAAP operating income for the quarter was $5.4 million, exceeding the high end of guidance and reflecting a non-GAAP operating margin of 17% [41] - The company ended the quarter with zero debt and over $68 million in cash and securities, indicating a strong balance sheet [5][41] Business Line Data and Key Metrics Changes - The Mortgage Suite generated $18.8 million in revenue for Q4 2025, up 3% year-over-year, aided by a return to growth and solid funded loan growth of 11% [39][40] - Consumer Banking Suite revenue was $11.5 million, representing a 21% year-over-year growth, although it experienced a sequential decline of 10% from Q3 due to customer churn and seasonality [40] Market Data and Key Metrics Changes - The overall pipeline for Blend's services is up about 40% year-over-year, with a notable shift towards bundled deals across mortgage and consumer banking [9] - The company is seeing a structural shift in how financial institutions view their technology stack, with a focus on scalable business models [10] Company Strategy and Development Direction - Blend is focusing on an "agent-first" approach, aiming to automate complex processes in lending and improve efficiency for customers [16][18] - The launch of Blend Autopilot aims to enhance the origination process by automating document processing and compliance checks, which is expected to significantly reduce operational costs for customers [20][31] - The company is committed to maintaining a lean cost structure while investing in technology to drive growth and efficiency [5][46] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the mortgage market, anticipating continued growth driven by stability in the customer base and new deployments [43] - The company is preparing for potential market recovery, with a focus on leveraging AI to enhance internal processes and customer offerings [46][50] Other Important Information - Blend repurchased 5.1 million shares worth approximately $16 million in Q4, reflecting confidence in the long-term value of the business [42] - A material weakness in revenue processes was identified, which will be disclosed in the upcoming 10-K filing [49] Q&A Session Summary Question: How much of the $11,000 cost in the current process is targetable with agentic capabilities? - Management indicated that a significant portion of the operational costs could be reduced by improving efficiency through automation, with ongoing updates expected to enhance capabilities [52][53] Question: What to expect regarding incremental operating leverage as volume dynamics recover? - Management noted that Q1 serves as a new baseline for operating leverage, with variable costs scaling with revenue and a focus on where to invest for efficiencies [56][58] Question: Can you provide insights on the new mortgage customers won in the quarter? - Management highlighted that the commitment to innovation and customer success was key in winning new customers, emphasizing the importance of ongoing investment in technology [63][64] Question: What is the uptake level for the new Rapid products? - Management reported good uptake for Rapid products, which are designed to enhance customer experiences in home equity and mortgage refinances, although significant change management is required [65][68] Question: How does the partnership with OpenAI Better.com validate Blend's business model? - Management views the partnership as validation of the opportunity in the space, emphasizing the difference between building technology and integrated software solutions [82]

Financial Data and Key Metrics Changes - The company reported third quarter revenue of $408 million, representing a 143% increase year-over-year, or a 6% increase on a pro forma basis [31] - Adjusted EBITDA for Q3 was $44 million, up from $22 million in the same quarter last year, with an adjusted EBITDA margin of 11% [37] - Funded backlog grew to $1.1 billion, with a total of $4.6 billion in year-to-date awards, positioning the company for a record fourth quarter [42] Business Line Data and Key Metrics Changes - The Autonomous Systems segment accounted for 68% of overall revenue, with significant growth driven by UAS products, including Puma, JUMP 20, and Switchblade systems [11][32] - The Space, Cyber, and Directed Energy segment recognized $121.9 million in revenue, reflecting a 19% decline year-over-year due to the SCAR program's stop work order [32][21] - The company expects strong demand for its Switchblade family of products, with a recent $186 million contract awarded for production units [66] Market Data and Key Metrics Changes - The demand for AI-enabled autonomous drones and counter-UAS solutions is unprecedented, with the company well-positioned to capitalize on this opportunity [6][7] - The company is actively engaged with international allies, including Taiwan, Japan, and South Korea, for autonomous systems to support their national security needs [15][16] - The company anticipates continued strong demand for its Titan family of products, with plans to increase manufacturing capacity significantly [16] Company Strategy and Development Direction - The company is transitioning certain programs to commercial product solutions to improve long-term profitability and market adoption [6][10] - The strategy includes scaling manufacturing to meet rising demand and focusing on delivering best-in-class solutions that align with customer mission objectives [8][25] - The company is committed to developing innovative capabilities and transitioning them to commercial offerings, which has been a successful strategy in the past [10][11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that the results fell below expectations due to revenue timing and adjustments in the Space business, but expressed confidence in achieving record fourth quarter revenue [4][25] - The urgency for defense capabilities has increased due to current geopolitical conflicts, positioning the company to meet critical defense needs [25][70] - Management remains optimistic about the growth trajectory, citing a diversified business model and strong demand across various product lines [30][52] Other Important Information - The company is in discussions with the U.S. Space Force regarding the Badger phased array antenna system, which has been paused for contract negotiations [9] - A non-cash goodwill impairment of $151 million was recorded due to the SCAR program's stop work order, impacting the financial outlook [29][30] - The company is actively integrating BlueHalo and realizing synergies from the acquisition, which is expected to enhance growth potential [24] Q&A Session Summary Question: Long-term prospects of SCDE without SCAR - Management indicated that the situation with the SCAR program is evolving, and they remain bullish on the phased array BADGER system's importance and potential for future contracts [50] Question: Revenue expectations from SCAR for fiscal 2026 - Management stated that the impact of SCAR on fiscal 2026 revenue has been factored into guidance, and it is expected to be less than 5% of total revenue [63][64] Question: Progress on Switchblade family products and LASSO program - Management confirmed active engagement with the U.S. Army on Switchblade products and expressed confidence in their position for future orders [66][68] Question: Demand acceleration due to the Iran conflict - Management noted an unprecedented increase in requests for proposals and demand for various products, including Freedom Eagle-1 and Red Dragon, due to the conflict [70] Question: Updates on directed energy portfolio and key programs - Management highlighted strong demand for LOCUST and other directed energy systems, emphasizing their unique market position and ongoing production efforts [77]

Financial Data and Key Metrics Changes - The company reported Q4 revenue of $38.5 million, reflecting a 32% year-over-year increase, and full-year revenue of $145.9 million, representing a 40% year-over-year growth [11][26] - Annual recurring revenue (ARR) at the end of 2025 was $120.5 million, showing a 21% year-over-year growth [11][30] - Adjusted EBITDA for 2025 was $11.1 million, compared to a loss of $21 million in 2024, marking a $32 million improvement [12][30] - Total cash equivalents and marketable securities increased by $12.8 million sequentially in Q4 to $69 million, indicating strong cash collection efforts [12][31] Business Line Data and Key Metrics Changes - The company added over 60 new customers in Q4, bringing the total to over 1,200 customers globally [13][56] - The fourth quarter saw a 13% year-over-year increase in remaining performance obligation (RPO), reaching $293.4 million [13][30] - The company reported strong demand for its Gen Two Express platform, with existing customers upgrading [13][30] Market Data and Key Metrics Changes - The company continues to expand in the education sector, adding 12 new school districts and 3 universities in Q4, screening approximately 300 million students and visitors throughout the year [16][17] - In healthcare, the company is now screening over 1 million patients, healthcare workers, and visitors daily across medical facilities [17] - The sports and live entertainment market saw the addition of 65 new customers in 2025, with nearly 1.5 million visitors screened daily [19][20] Company Strategy and Development Direction - The company aims to build a scalable, high-growth hardware-enabled subscription business, focusing on modern technology-enabled security solutions [6][7] - The strategy includes investing in product innovation and expanding the customer base while maintaining a disciplined approach to working capital management [24][25] - The company anticipates that weapon screening will become standard infrastructure in certain buildings, similar to sprinkler systems [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued demand for security solutions due to escalating threat levels in public venues and workplaces [6][7] - The company raised its revenue guidance for 2026 to a range of $172 million to $178 million, expecting ARR growth of 20% to 25% [24][32] - Management highlighted the importance of innovation in weapon detection accuracy and cost as key to maintaining a competitive edge [25] Other Important Information - The company will host its 2026 Investor Day on June 9, 2026, to provide updates on strategy and product innovation [5] - The company is transitioning to a direct fulfillment model for purchase subscriptions, which is expected to enhance revenue and gross profit over time [26][30] Q&A Session Summary Question: Context for raised revenue guidance despite modest sequential ARR growth - Management anticipates ARR to accelerate throughout the year due to changes in pricing and fulfillment models [41][43] Question: Overall adjusted gross margins trend for 2026 - Management expects gross margins to be in line or slightly better in 2026 compared to 2025, with more gross profit dollars being pushed into RPO [44][45] Question: Timing for production from Plexus relationship - Management confirmed that full ramp with Plexus is expected in the second half of 2026, which will provide a tailwind to gross margins [46][47] Question: Mix between new logos and existing customers - Management indicated a consistent 50/50 split between new customer acquisitions and existing customer expansions [55][69] Question: Impact of AHA certification on hospital deals - Management expressed optimism that the AHA partnership will accelerate hospital deals, especially with regulatory changes mandating weapon screening [70]

Financial Data and Key Metrics Changes - Total net sales for Q4 2025 were $11.5 million, up 12% from $10.2 million in Q4 2024 [20] - Full year 2025 total net sales reached $51.5 million, a 19% increase from $43.4 million in 2024 [20] - Adjusted EBITDA for the full year was positive $1.2 million, compared to negative $1.5 million in 2024 [28] - The company ended 2025 with over $20 million in cash, an increase of $6 million from the end of 2024 [28] Business Line Data and Key Metrics Changes - Food Service Technology (FST) sales for Q4 were $4.8 million, up 12% year-over-year [20] - FST recurring revenue reached $3.4 million in Q4, a 24% increase from $2.7 million in the prior year [21] - Casino and gaming sales for Q4 were $5.4 million, up 13% from $4.8 million in Q4 2024 [22] - POS automation sales increased 47% year-over-year to $606,000 in Q4 [23] Market Data and Key Metrics Changes - FST net sales for the full year were $19.3 million, a 20% increase from $16.1 million in 2024 [21] - Casino and gaming sales for the full year were $26.9 million, up 32% year-over-year [23] - The installed base of terminals is approximately 40,000 legacy units, presenting opportunities for upgrades [12] Company Strategy and Development Direction - The company is focusing on revenue growth in the FST vertical, with software as the primary growth engine [4] - Plans to enhance software offerings and introduce new applications following the acquisition of the BOHA! source code [6] - Targeting positive adjusted EBITDA for 2026 while making disciplined investments in sales and marketing [7] - Emphasis on competitive pricing and strategic partnerships in high-potential sub-verticals such as quick-service restaurants [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the direction of the business in 2026, particularly around FST software initiatives [18] - The company expects net sales for 2026 to be between $55 million and $57 million, with adjusted EBITDA projected between $800,000 and $1.5 million [18] - Management highlighted the importance of fiscal discipline and creating shareholder value through prudent growth [19] Other Important Information - The company is transitioning from a hardware-centric focus to a software-driven solutions provider [10] - New Chief Marketing Officer Dana Loof has been appointed to lead marketing and growth initiatives [14] - The company is exploring an application store model for terminals to drive additional software revenue streams [10] Q&A Session Summary Question: How do you see AI programming tools helping your business? - The company uses AI internally to improve efficiency in coding and application development [31] - AI tools will be added to products to help clients optimize decision-making [32] Question: How does the company view competition from AI? - Management believes that while AI can assist in basic coding, creating engaging applications still requires skilled personnel [33] - The company sees AI as an opportunity to enhance customer experience rather than a threat [34]

Financial Data and Key Metrics Changes - For the full year 2025, net revenues from continuing operations were $20.4 million, down from $23.2 million in 2024, reflecting an 11.9% decrease [3][11] - Net income from continuing operations improved to nearly $700,000 in 2025, compared to a net loss of $8.6 million in 2024, driven by disciplined cost management and a $3 million tax benefit [4][12] - For Q4 2025, net revenues from continuing operations were $4.6 million, down from $5.9 million in Q4 2024, while net income for the quarter was $2.5 million, compared to a net loss of $3 million in the previous year [4][10] Business Line Data and Key Metrics Changes - The company has exited certain markets to focus on higher-quality revenue streams, which contributed to the decrease in revenue but improved overall financial performance [4][11] - Adjusted EBITDA from continuing operations improved to -$427,000 in Q4 2025 from -$2.3 million in Q4 2024, indicating better operational efficiency [10] Market Data and Key Metrics Changes - The prediction markets opportunity is estimated to have a trading volume of $30 billion to $40 billion in 2025, with long-term U.S. market volume potentially reaching hundreds of billions [6] - The company is targeting a total addressable market (TAM) estimate of about $10 billion annually based on contract trading volume, which is considered conservative [23] Company Strategy and Development Direction - The company is focused on expanding into prediction markets in the U.S. and iGaming in Ontario, with plans to provide updates on launch timings [2][3] - A recent capital raise of $26 million is intended to support market expansion and product development while maintaining a disciplined approach to cost control [14][15] - The company aims to prioritize operational efficiency and strong unit economics rather than pursuing growth in less favorable regulatory environments [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the significant opportunities in prediction markets and the groundwork laid for future growth [16] - The company is preparing for a rapid revenue ramp in 2026 and beyond, with a focus on execution and strategic initiatives [9][16] Other Important Information - The company has made key leadership appointments to strengthen its operational execution and marketing capabilities [8] - A partnership with Crypto.com for launching an event-based trading product in the U.S. is seen as a strategic inflection point for the company [5] Q&A Session Questions and Answers Question: Can you elaborate on your marketing strategy for prediction markets? - The company plans to leverage distribution channels like Forever Network and Lines.com, emphasizing performance marketing expertise in regulated markets [18] Question: How large do you see the U.S. prediction markets? - Management believes the market is larger than current estimates suggest, with a TAM of about $10 billion annually based on contract trading volume [23] Question: Can investors expect a material step-up in revenue growth? - Management indicated a strong internal belief in the opportunity, suggesting that significant revenue growth is anticipated as the company scales its operations [26]

Financial Data and Key Metrics Changes - The company ended 2025 with $25.7 million in cash equivalents and short-term investments, managing its operating plan to extend its runway through Q4 2026 [30] Business Line Data and Key Metrics Changes - The CBeyond program has shown a clinically meaningful 3% improvement in weight loss over semaglutide alone at 26 weeks, with a 22.3% mean weight loss in the combination arm over 52 weeks [6][18] - Participants on semaglutide alone regained 38.7% of weight over 13 weeks after stopping therapy, while those on the combination of nimacimab plus semaglutide only regained 17.8% [18] Market Data and Key Metrics Changes - The company is positioning nimacimab as a complementary therapy to GLP-1s, targeting second-line add-on settings for patients who have not achieved their weight loss goals with first-line therapies [20][21] Company Strategy and Development Direction - The company is expanding the CBeyond study to include new intravenous cohorts to rapidly generate safety and pharmacokinetic data at higher exposures [14] - The focus is on developing a co-formulation of nimacimab using Halozyme's ENHANZE technology to facilitate high-volume subcutaneous injections [16] - The company aims to determine the exposure and duration of peripheral CB1 engagement required to produce clinically meaningful efficacy [34] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of generating clinical data to support nimacimab's potential in the anti-obesity medicine landscape, particularly in combination with GLP-1s [14][19] - The feedback from the FDA has helped refine the Phase 2b protocol, particularly regarding combination therapy development [17] Other Important Information - The company is advancing its first antibody peptide conjugate program, which aims to combine nimacimab's mechanism of action with a GLP-1 receptor agonist [25][28] Q&A Session Summary Question: Plans to share data from higher dose cohorts and status of formulation work - The company is expanding into the Part C expansion study to generate data on higher exposures and expects updates by Q4 2026 [38][39] - The formulation work with Halozyme is ongoing and expected to be ready for the Phase 2b study [40][41] Question: Concerns about dose levels in the expansion study - Management believes the selected doses are sufficient for the Phase 2b selection, but they are continuing to evaluate higher dosing [48] Question: Profile and goals for the new program - The new program is seen as long-term optionality, with nimacimab remaining the core value driver [52] Question: Importance of peripheral tissues for nimacimab's clinical effect - Adipose tissue and liver are critical for nimacimab's effects, with different profiles expected for monotherapy versus combination therapy [61] Question: Use of IV in the Part C phase of the study - IV is being used for the fastest generation of high exposure PK and safety information, with plans for subcutaneous delivery in Phase IIb [65]

Financial Data and Key Metrics Changes - In 2025, SIGA reported total product revenues of approximately $88 million, which includes $53 million from oral TPOXX, $26 million from IV TPOXX, and $6 million from international oral TPOXX sales [3][9] - The company achieved a pretax operating income of approximately $24 million and a net income of approximately $23 million for the year, resulting in a fully diluted income per share of $0.32 [10] - As of December 31, 2025, SIGA maintained a strong cash position with approximately $155 million in cash and no debt [10] Business Line Data and Key Metrics Changes - The primary revenue driver for SIGA in 2025 was product deliveries to the U.S. Strategic National Stockpile (SNS) under the BARDA contract, which accounted for the majority of product revenues [9] - The company secured $27 million in funding to support pediatric formulation development and IV technology transfer efforts during 2025 [4] Market Data and Key Metrics Changes - SIGA continues to engage with international governments and stakeholders to strengthen health security, with a recent $13 million order from a country in the Asia-Pacific region [5][19] - The company is actively discussing stockpiling of TPOXX with various potential customers globally, reflecting an increased focus on preparedness strategies due to rising biothreat risks [5][20] Company Strategy and Development Direction - SIGA's strategy focuses on supporting global preparedness for biological threats, particularly smallpox, through sustained investment and stockpiling of antiviral treatments [2][4] - The company aims to maintain financial strength while advancing strategic initiatives that support long-term value creation [8] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of readiness in the face of heightened geopolitical risks and biological threats, emphasizing the critical role of TPOXX in emergency situations [3] - The company expects to continue its productive relationship with the U.S. government and anticipates a new procurement contract to further support stockpiling efforts [4][15] Other Important Information - The European Medicines Agency (EMA) is expected to meet in March to issue a recommendation regarding the marketing authorization of Tecovirimat SIGA, with expectations of a positive benefit-risk balance [6] - SIGA is advancing its pediatric program to develop an oral suspension formulation for children, with a phase 1 study recently initiated [8] Q&A Session Summary Question: Update on the timing of the next U.S. government RFP for TPOXX - Management indicated that smallpox preparedness remains a focus for the U.S. government, but no specific timing details for the next RFP were available [14][15] Question: Capital allocation priorities looking ahead - Management stated that capital management will remain disciplined and flexible, with no immediate updates on special cash dividends [16] Question: Openness to acquisitions or in-licensing opportunities - Management confirmed that the company is open to pursuing acquisitions or in-licensing opportunities while maintaining a disciplined and strategic approach [17] Question: Details on the recent $13 million TPOXX order - Management noted that the order is from a repeat customer under a multi-year contract, but specific details could not be disclosed for security reasons [19][20] Question: Expectations for additional international orders - Management expressed that while additional international sales may occur in 2026, the processes can be complex and time-consuming [20]

Financial Data and Key Metrics Changes - In 2025, the company achieved revenues of $501 million, a 4.2% increase from 2024, with adjusted net income of $18.1 million or $0.50 per diluted share [18][19] - Gross margin expanded by over 260 basis points, and adjusted EBITDA rose approximately 10% year-over-year, reflecting improved operating leverage and cost discipline [5][12] - Free cash flow reached $31.4 million, up approximately 45% year-over-year, demonstrating strong cash generation capabilities [6][21] Business Line Data and Key Metrics Changes - The company gained delivery market share by nearly 300 basis points, despite total industry deliveries declining to approximately 31,000 railcars from 42,000 in the prior year [14] - The acquisition of Carli Railcar Components expanded aftermarket capabilities and is expected to contribute $13 million-$15 million in revenue for 2026 [9][30] - The company reported a backlog of 1,926 railcars valued at $137.5 million, providing visibility into 2026 production [10][16] Market Data and Key Metrics Changes - North American new railcar orders totaled approximately 20,000 units in 2025, down from roughly 25,000 in the prior year, indicating a moderation in industry orders [15] - The company expects industry deliveries in 2026 to be in the range of 25,000-30,000 railcars, with a corresponding market share increase to approximately 15%-16% [49][50] Company Strategy and Development Direction - The company aims to maintain consistent margin performance, generate strong free cash flow, and expand its aftermarket and tank capabilities [11][12] - The strategic roadmap includes building a more robust recurring revenue platform through acquisitions and enhancing customer relationships [9][12] - The company is focused on progressing tank car readiness for retrofit programs, which are expected to contribute to long-term goals [10][11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging year for the North American rail market but emphasized strong underlying fundamentals and the company's resilience [4][11] - The company anticipates a normalization of demand as fleets age and replacement needs reassert themselves, positioning itself well to capitalize on emerging opportunities [11][12] - For 2026, the company forecasts revenues between $500 million and $550 million, reflecting a 4.8% year-over-year increase at the midpoint [27] Other Important Information - The company ended 2025 with $64.3 million in cash and low net debt, operating at the low end of its targeted leverage range [21][24] - Capital expenditures for 2026 are expected to be between $7 million and $10 million, focusing on maintenance and strategic investments [25] Q&A Session Summary Question: What is the revenue estimate for the aftermarket business in 2026? - The company expects approximately $40 million-$41 million for the aftermarket business in 2026 [30] Question: Will interest expense decline in 2026? - The company anticipates interest expense to decrease to around $14 million-$15 million due to debt repayments [31][32] Question: What drove margin expansion during the quarter? - Margin expansion was primarily driven by productivity and operational improvements rather than just a higher proportion of higher-margin cars [39] Question: What is the outlook for industry deliveries in 2026? - The company expects industry deliveries to be in the range of 25,000-30,000 railcars, with an increase in market share [49][50] Question: How long does it take for orders to convert into deliveries? - Order conversion can take anywhere from a year down to days, depending on customer needs and planning [72]